Brain State Technologies05/17/2013
Brain State Technologies: What Is Brainwave Optimization
Over 50,000 people worldwide have experienced breakthroughs utilizing BrainState Technologies Brainwave Optimization with RTB™ (Real Time Balancing). This process is an effective, holistic and non-invasive method of achieving greater brain balance and harmony. Improving brain function has shown to help with injuries, disorders, stress, pain, anxiety, sleeplessness, addictive dependencies, challenges to learning and performance.
Dr. Adelson has been recognized as one of the foremost experts on pediatric head injury , lecturing around the United States and the world. Now he joined Phoenix Children's to expand a program that surpasses the typical model of pediatric care. For some, it's playing a musical instrument. For others, it's painting. But for P. David Adelson, MD, FACS, FAAP, the director of the Hospital's Barrow Neurological Institute and chief of neurosurgery, his passion is a bit atypical. "My hobby is neuroscience," he says. "The heart's a pump, the kidney's a filter – those are all simple functions which are there to support who we are and what we do." But the brain controls it all, he says. "I just looked at the brain and neurosciences as the next frontier; studying something of which I would never get bored." Dr. Adelson has been recognized as one of the foremost experts on pediatric head injury clinical management, lecturing around the United States and the world. He has been published in numerous medical and scientific journals defining "state-of-the art" in the care of children with traumatic brain injuries. The path to Phoenix Children's Hospital Dr. Adelson came to Phoenix in January from Pittsburgh, where he served as the A. Leland Albright Endowed Professor of Neurosurgery/Pediatric Neurosurgery at Children's Hospital of Pittsburgh and Vice Chairman, (Research) at the University of Pittsburgh School of Medicine , one of the most prominent neurosurgical departments in the country.
DNA on a Shirt
DNA on a SHIRT is an innovative, unique company that created wearable and wallable™ genetic art that couples art and science, meshing fashion and education in the process. Through their various DNA inspired T-shirts and art prints, our mission is to create a catalyst for engagement by engaging art, science and people. Our products include art pieces and T-shirts that showcase the DNA fingerprint of people, pets, plants and zoo animals.
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart. The company was formed in 2001 by world-renowned heart surgeon Jack G. Copeland, MD, interventional cardiologist Marvin J. Slepian, MD, and biomedical engineer Richard G. Smith, MSEE, CCE, to commercialize the SynCardia temporary Total Artificial Heart .
Leslie Boyer, MD 2013 Arizona Bioscience Researcher of the Year
In 2013, Dr. Leslie Boyer was been named one of 30 heroes of rare diseases by the Food and Drug Administration’s Office of Orphan Products Development. Her work includes a clinical studies program conducted throughout Arizona with protocols for placebo-controlled, double-blind trials, open-label studies, historical control studies, and the statewide STING project. She has coordinated phase 2 and phase 3 multicenter clinical trials of pit viper antivenom, developed the Antivenom Index, and participated in the establishment of the Pan-American Lymphotoxinology Taskforce. Boyer, who is a member of the UA’s BIO5 Institute, has focused her scientific career on venomous bites and stings, which are often unrecognized public health issues. She began by developing public education programs that offer poison and toxin emergency treatment advice. In 2004 and 2005, with an FDA Orphan Product grant, she led a team that conducted clinical studies leading to the marketing approval of the first scorpion antivenom – representing one of more than 40 products developed through orphan grant-sponsored research.
Raymond L. Woosley, MD, PhD - 2012 AZBio Pioneer
Raymond L. Woosley earned a Ph.D. in Pharmacology from the University of Louisville and an M.D. from the University of Miami. He began his career as the first scientist in the US operations for Glaxo, now known as GlaxoSmithKline. Dr. Woosley specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University where he rose to the rank of Professor of Medicine. At Georgetown University he served as Chairman of the Department of Pharmacology and in 2000 was appointed Associate Dean for Clinical Research. In 2001 he became Vice President for Health Sciences at the University of Arizona and Dean of the College of Medicine. In January of 2005 he assumed the position of President of The Critical Path Institute (C-Path), a non-profit corporation formed by the Food and Drug Administration, SRI, International and the University of Arizona to accelerate the development of safe innovative medicines. Since 1999, he has directed one of seven federally-funded (Agency for Healthcare Research and Quality) Centers for Education and Research on Therapeutics (CERT).Under Dr. Woosley’s leadership, C-Path (the Critical Path Institute) orchestrated the acceleration of medical product development through a unique collaborative process among industry, academia, and the FDA. Our collaborations among 6 global consortia, 1000+scientists, and 41 companies has already produced these notable successes: First preclinical safety biomarkers (7) qualified by the FDA, EMA, and PMDA (the Japanese counterpart) First CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard First and largest open database of CDISC aggregated clinical trial data for Alzheimer’s disease (6,100 patients and 22 clinical trials) Read more First drug-disease trial model & clinical trial simulation tool submitted and under review by the FDA First imaging biomarker for trial enrichment qualified by the EMA Dr. Woosley’s research has investigated the basic and clinical pharmacology of drugs for the treatment of arrhythmias and the cardiac toxicity of drugs, and has been published in over 260 publications. His research discovered the mechanism of the toxicity of the antihistamine Seldane®. He is the recipient of the Rawls-Palmer Award from the American Society of Clinical Pharmacology and Therapeutics for his contributions to medicine and the FDA Commissioner’s Special Citation for his work to advise the agency on the toxicity of dietary supplements containing ephedra. Dr. Woosley is a Past-President of the Association for Medical School Pharmacology and the American Society for Clinical Pharmacology and Therapeutics. He has served on numerous boards including the US Pharmacopeia. He is a member of the Biodesign Institute at Arizona State University. As a member of the University of Arizona’s Sarver Heart Center and Bio5 Institute, he conducts research on the prevention of adverse drug interactions.